In a nutshell This study examined the use of the combination of bendamustine (Treanda) and rituximab (Rituxan) as a firstline treatment in patients with follicular or mantle cell lymphoma. This study concluded that this treatment combination was more effective than the standard treatment of rituximab plus CHOP chemotherapy. Some background The...
Read More
In a nutshell This study compared different chemotherapy regimens and rituximab (Rituxan) for the initial treatment of advanced follicular lymphoma. This study concluded that the combinations R-CHOP and R-FM were more effective than R-CVP. R-CHOP was associated with fewer severe side effects than R-FM. Some background Follicular lymphoma (FL) is...
Read More
In a nutshell This study assessed the effectiveness of using escalated BEACOPP plus rituximab chemotherapy in patients with advanced stage Hodgkin Lymphoma. The study concluded that adding rituximab to the standard escalated BEACOPP regimen did not significantly improve time to disease progression. Some background Hodgkin Lymphoma (HL) is...
Read More
In a nutshell This review discussed the current and future treatment options for advanced Hodgkin lymphoma (stage III or IV). Some background While early-stage Hodgkin lymphoma has very high remission rates, rates for advanced disease are generally lower. The standard treatment option for advanced Hodgkin lymphoma is ABVD chemotherapy...
Read MoreIn a nutshell This study compared three chemotherapy combinations, standard dose BEACOPP, increased dose BEACOPP, and COPP-ABVD, for advanced Hodgkin lymphoma. The authors concluded that increased-dose BEACOPP was more effective. Some background The standard chemotherapies for advanced Hodgkin lymphoma (stage III or IV or those with additional...
Read More
